These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21076190)

  • 1. Dose perturbations and image artifacts caused by carbon-coated ceramic and stainless steel fiducials used in proton therapy for prostate cancer.
    Cheung J; Kudchadker RJ; Zhu XR; Lee AK; Newhauser WD
    Phys Med Biol; 2010 Dec; 55(23):7135-47. PubMed ID: 21076190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of dose perturbations and the radiographic visibility of potential fiducials for proton radiation therapy of the prostate.
    Huang JY; Newhauser WD; Zhu XR; Lee AK; Kudchadker RJ
    Phys Med Biol; 2011 Aug; 56(16):5287-302. PubMed ID: 21799236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monte Carlo simulations of the dosimetric impact of radiopaque fiducial markers for proton radiotherapy of the prostate.
    Newhauser W; Fontenot J; Koch N; Dong L; Lee A; Zheng Y; Waters L; Mohan R
    Phys Med Biol; 2007 Jun; 52(11):2937-52. PubMed ID: 17505081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microscopic gold particle-based fiducial markers for proton therapy of prostate cancer.
    Lim YK; Kwak J; Kim DW; Shin D; Yoon M; Park S; Kim JS; Ahn SH; Shin J; Lee SB; Park SY; Pyo HR; Kim DY; Cho KH
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1609-16. PubMed ID: 19616746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical investigation for developing injectable fiducial markers using a mixture of BaSO4 and biodegradable polymer for proton therapy.
    Ahn SH; Gil MS; Lee DS; Han Y; Park HC; Sohn JW; Kim HY; Shin EH; Yu JI; Noh JM; Cho JS; Ahn SH; Choi DH
    Med Phys; 2015 May; 42(5):2626-37. PubMed ID: 25979054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the dosimetric impact of a Ni-Ti fiducial marker in carbon ion and proton beams.
    Herrmann R; Carl J; Jäkel O; Bassler N; Petersen JB
    Acta Oncol; 2010 Oct; 49(7):1160-4. PubMed ID: 20831508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fiducial markers in prostate for kV imaging: quantification of visibility and optimization of imaging conditions.
    Chen Y; O'Connell JJ; Ko CJ; Mayer RR; Belard A; McDonough JE
    Phys Med Biol; 2012 Jan; 57(1):155-72. PubMed ID: 22127351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a novel liquid fiducial marker for multimodal image guidance in stereotactic body radiotherapy of prostate cancer.
    De Roover R; Crijns W; Poels K; Peeters R; Draulans C; Haustermans K; Depuydt T
    Med Phys; 2018 May; 45(5):2205-2217. PubMed ID: 29537613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Visibility and Artifacts of 11 Common Fiducial Markers for Image Guided Stereotactic Body Radiation Therapy in the Abdomen.
    Slagowski JM; Colbert LE; Cazacu IM; Singh BS; Martin R; Koay EJ; Taniguchi CM; Koong AC; Bhutani MS; Herman JM; Beddar S
    Pract Radiat Oncol; 2020; 10(6):434-442. PubMed ID: 31988039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose perturbations from implanted helical gold markers in proton therapy of prostate cancer.
    Giebeler A; Fontenot J; Balter P; Ciangaru G; Zhu R; Newhauser W
    J Appl Clin Med Phys; 2009 Jan; 10(1):2875. PubMed ID: 19223836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosimetric impact of tantalum markers used in the treatment of uveal melanoma with proton beam therapy.
    Newhauser WD; Koch NC; Fontenot JD; Rosenthal SJ; S Gombos D; Fitzek MM; Mohan R
    Phys Med Biol; 2007 Jul; 52(13):3979-90. PubMed ID: 17664589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intraprostatic fiducials in stereotactic radiotherapy for prostate cancer].
    Cordoba A; Pasquier D; Nickers P; Lacornerie T; Lartigau É
    Cancer Radiother; 2016 Dec; 20(8):815-819. PubMed ID: 27793529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy.
    Habermehl D; Henkner K; Ecker S; Jäkel O; Debus J; Combs SE
    J Radiat Res; 2013 Jul; 54 Suppl 1(Suppl 1):i61-8. PubMed ID: 23824129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current modulated volume-of-interest imaging for kilovoltage intrafaction monitoring of the prostate.
    Parsons D; Stevens MT; Robar JL
    Med Phys; 2017 Apr; 44(4):1479-1493. PubMed ID: 28133744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose perturbation effect of metallic spinal implants in proton beam therapy.
    Jia Y; Zhao L; Cheng CW; McDonald MW; Das IJ
    J Appl Clin Med Phys; 2015 Sep; 16(5):333-343. PubMed ID: 26699317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetric impact of fiducial markers in patients undergoing photon beam radiation therapy.
    Vassiliev ON; Kudchadker RJ; Kuban DA; Frank SJ; Choi S; Nguyen Q; Lee AK
    Phys Med; 2012 Jul; 28(3):240-4. PubMed ID: 21875820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of kV cone-beam ct performance for prostate IGRT: a comparison of automatic grey-value alignment to implanted fiducial-marker alignment.
    Shi W; Li JG; Zlotecki RA; Yeung A; Newlin H; Palta J; Liu C; Chvetsov AV; Olivier K
    Am J Clin Oncol; 2011 Feb; 34(1):16-21. PubMed ID: 21189455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of intra- or periprostatic calcifications in image-guided radiotherapy for prostate cancer.
    Hanna SA; Neves-Junior WF; Marta GN; Haddad CM; da Silva JL
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1208-16. PubMed ID: 21640492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the dose perturbation around gold and steel fiducial markers in a medical linac through Geant4 Monte Carlo simulation.
    Pontoriero A; Amato E; Iatí G; De Renzis C; Pergolizzi S
    J Xray Sci Technol; 2015; 23(2):135-40. PubMed ID: 25882726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of MRI visibility and artifacts at 3T of liquid fiducial marker in a pancreas tissue-mimicking phantom.
    Schneider S; Jølck RI; Troost EGC; Hoffmann AL
    Med Phys; 2018 Jan; 45(1):37-47. PubMed ID: 29136287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.